SCHEMBL2117377

SCHEMBL2117377

COc1ccc(CN2C(=O)CN=C(c3cn[nH]c3)c3cc(Cl)ccc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.55
LMNA P02545 2/20 0.52
OPRK1 P41145 2/20 0.47
NR1I2 O75469 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
OPRM1 P35372 1/20 0.47
MAPT P10636 3/20 0.47
PTGDR2 Q9Y5Y4 2/20 0.46
GAA P10253 2/20 0.46
TSPO P30536 1/20 0.46
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
CACNA1F O60840 1/20 0.44
ALB P02768 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607167 0.89 TP53 (0.64) TP53LMNAOPRK1NR1I2ADORA3
SCHEMBL13086656 0.89 TP53 (0.42) TP53LMNAOPRK1NR1I2ADORA3
SCHEMBL5361219 0.86 TP53 (0.72) TP53LMNAOPRK1NR1I2ADORA3
SCHEMBL14064651 0.85 TP53 (0.65) TP53LMNAOPRK1NR1I2ADORA3
SCHEMBL11964655 0.85 TP53 (0.59) TP53LMNAOPRK1NR1I2ADORA3
SCHEMBL607145 0.85 TP53 (0.59) TP53LMNAOPRK1NR1I2ADORA3
SCHEMBL30327555 0.82 TP53 (0.64) TP53LMNAOPRK1NR1I2ADORA3
SCHEMBL608034 0.82 TP53 (0.53) TP53LMNAPTGDR2ALDH1A1SMN1; SMN2
SCHEMBL2119570 0.81 TP53 (0.54) TP53LMNAOPRK1NR1I2ADORA3
Isobutane SCHEMBL2119385 0.80 TP53 (0.51) TP53LMNAOPRK1NR1I2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604023-B2 1,4-benzodiazepinone compounds and their use in treating cancer THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2013-12-10 US disclosed
US-20120094982-A1 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-04-19 US disclosed
US-20120094982-A1 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-04-19 US disclosed
US-20120094982-A1 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-04-19 US disclosed
WO-2010121164-A2 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-10-21 WO disclosed
WO-2010121164-A2 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094982-A1 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER HTR4, HTR1A, HTR3B TP53 978/4885LMNA 2242/4885OPRK1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.